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marked murine ES cells (R1/129) and ES-CCE without marker
ﬂuorescence protein in vitro differentiation induced by TGF- (2
ng/ml), EGF (25 ng/ml), and -FGF (100 ng/ml) for 7 days.
IL10/ mice were injected with predifferentiated ES-YFP cells
and killed at 2 months postinjection. Serial frozen sections of
colon, small intestine, and thymus were made, and EYFP staining
was double detected using a confocol microscope and determined
by immunohistochemistry using anti-GFP antibody. Results:His-
topathologic analysis demonstrated improvement in colon tissue.
Fluorescent and confocal microscopy demonstrated presence of
the ES-EYFP cells in the colon, small intestine, liver, and thymus
tissues. Anti-GFP staining was also detected in these tissues. The
EYFP signal was not detected in sham and control IL10/
knock-out mice. Immune studies by ELISA demonstrated a
TH13TH2 shift suggesting immune recovery. Conclusion: Our
results suggest that the study of differentiation and repair potential
of embryonic stem cells in pathological Crohn’s disease model may
lead to an alternative therapeutic potential for the treatment and
prevention of inﬂammatory bowel disease.
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HUMAN HEMATOPOIETIC STEM CELLS CAN BE EXPANDED EX VIVO
USING RECOMBINANT TAT-HOXB4 PROTEIN
Krosl, G.1; Giard, M.-P.1; Krosl, J.2; Humphries, R.K.3; Sauvageau,
G.2; Roy, D.C.1 1. Hopital Maisonneuve-Rosemont Research Centre,
Montreal, QC, Canada; 2. IRIC/Universite de Montreal, Montreal,
QC, Canada; 3. Terry Fox Laboratory, BC Cancer Agency, Vancouver,
BC, Canada.
In mouse bone marrow transplantation models, engineered over-
expression of HOXB4 has been one of the most potent stimulator
of hematopoietic stem cell (HSC) expansion identiﬁed to date. The
addition of soluble recombinant TAT-HOXB4 protein was also
recently reported to enable rapid in vitro expansion of murine
HSCs that retain their in vivo proliferation and differentiation
capacity. However, the expansion potential of TAT-HOXB4 has
always been tested on murine cells, and the capacity of this recom-
binant protein to expand human hematopoietic stem cells has
remained hypothetical. To determine the ability of recombinant
TAT-HOXB4 protein to promote human HSC expansion, we
performed a series of experiments using CD34 populations iso-
lated from healthy volunteers. The CD34 cell populations were
cultured for 4 days in ex vivo 15 medium supplemented with stem
cell factor (300 ng/mL) and G-CSF (50 ng/mL) in the presence or
absence of TAT-HOXB4 protein (50 nmol/L). In response to
TAT-HOXB4, total numbers of mononuclear cells demonstrated a
modest but distinct 2-fold increase compared with controls. TAT-
HOXB4 treatment had a major proliferation enhancing effect on
the more primitive cell populations such as CFU-GEMM, BFU-E,
and BFU-Meg, which numbers increased 26.5- 	 1.4-fold
(mean 	 SD), 2.2- 	 0.7-fold, and 2.1- 	 0.2-fold, respectively,
over their input values, and 19.1- 	 1.3-fold, 2.7- 	 0.7-fold, and
31- 	 3.4-fold, respectively, compared with growth factor-only
controls. In response to TAT-HOXB4, the total numbers of
CD34CD38Lin cells increased 2.1- 	 0.7-fold above their
starting numbers, compared with a 1.5- 	 0.5-fold loss of this
population in control cultures. HSC numbers were enumerated at
the beginning, and after a 4-day TAT-HOXB4 treatment period
under the same conditions using a NOD/SCID repopulation assay.
In response to 50 nM TAT-HOXB4, NOD/SCID repopulating
cell (SRC) numbers increased 2-fold over their input values, com-
pared with a 9-fold loss in control cultures without TAT-HOXB4.
These results show that recombinant TAT-HOXB4 protein, even
when combined with a limited number of hematopoietic growth
factors, has the capacity to rapidly induce ex vivo expansion of
human stem cell and progenitor cell populations. They also pro-
vide the ﬁrst evidence that TAT-HOXB4 protein could be used to




ABDOMINAL CT IN THE CLINICAL EVALUATION OF ACUTE GRAFT-
VERSUS-HOST DISEASE (GVHD) OF THE GASTROINTESTINAL TRACT:
DIFFUSE SMALL INTESTINE INVOLVEMENT IS ASSOCIATED WITH POOR
OUTCOME
Shimoni, A.; Hertz, M.; Yeshurun, M.; Portnoy, O.; Hardan, I.;
Amitai, M.; Nagler, A.; Apter, S. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
Acute GVHD is the major treatment-related complication after
allogeneic stem-cell transplantation. Acute GVHD of GI tract is a
clinical diagnosis supported by histopathologic ﬁndings. The vol-
ume of diarrhea determines disease stage and prognosis; however,
its assessment is inconvenient and inaccurate. Moreover, patients
may present with atypical symptoms, whereas GI tract biopsies
may be falsely negative due to patchy involvement or may be
contraindicated in patients with severe thrombocytopenia. This
study was designed to determine the CT features associated with
acute GI GVHD and to evaluate its role in assessment of severity
and prognosis. A total of 34 consecutive patients with symptoms
suggestive of acute GI GVHD were evaluated by abdominal CT.
Of these 34 patients, 18 had clinical stage I-II and 14 had clinical
stage III-IV by the Glucksberg criteria; 32 patients had patholog-
ical ﬁndings on CT. The most consistent ﬁnding was thickening of
the bowel wall, which was limited to the small bowel (n  11) or
large bowel (n  5) or involved both segments (n  16). Involve-
ment was diffuse or segmental. Other manifestations included
intestinal dilatation (n  11), mucosal enhancement (n  3), and
gastric wall thickening (n  7). Extraintestinal ﬁndings included
mesenteric stranding (n  22), ascites (n  13), and biliary system
abnormalities (n  11). Ten patients had urinary excretion of
orally administered gastrograﬁn, which is not normally absorbed
by an intact intestine. Diffuse thickening of the small bowel wall
and/or any involvement of the large intestine were patterns asso-
ciated with severe clinical presentation. Eleven and 14 of the 16
patients with clinical stage III-IV had these patterns, compared to
5 and 7 of the 18 patients with stage I-II, respectively (P  .03).
Overall, 19 patients responded to immunesuppressive therapy.
Nine patients are alive; 25 died, 13 of complications directly re-
lated to GVHD. Diffuse small bowel disease was associated with
poor prognosis. Only 6 of 16 patients showing this pattern re-
sponded to therapy, compared with 13 of 18 patients without this
pattern (P  .05). The cumulative incidence of GVHD-related
death was 56% and 25%, respectively (P  .05). Overall survival
was not signiﬁcantly different in the 2 groups. In conclusion,
abdominal CT may have an important role in the diagnosis of
GVHD in atypical presentations and in the prognostic evaluation.
Diffuse small intestinal disease is associated with poor response to
therapy and GVHD-related mortality. CT ﬁndings may direct the
clinician in determining the therapeutic approach.
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SAFETY AND TOLERABILITY OF ANTIBACTERIAL PROPHYLAXIS DUR-
ING THE POSTENGRAFTMENT PHASE AFTER MYELOABLATIVE HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Bubalo, J.S.; Hayes-Lattin, B.; Curtin, P.T.; Leis, J.F.Mauro, M.J.;
Simic, A.Dunn, A.; Subbiah, N.; Allen, B.; Balleison, S.; Schubach, S.;
Maziarz, R.T. Oregon Health Science University Hospital, Portland,
OR.
Background: Bacterial infections are frequent complications of
the postengraftment phase after ablative allogeneic HSCT. This
pilot study investigated the safety and tolerability of administering
antibiotic (ABX) prophylaxis from when patients tolerated PO
medications after engraftment (ANC  1500/mm3 for 2 days)
through day 100. Methods: Twenty-three engrafted allogeneic
BMT patients at OHSU, received moxiﬂoxacin (MOXI) 400 mg
po daily. Drug was started on discontinuation of any ABX used for
the treatment of pre-enrollment bacterial infection or neutropenic
fever. Rates of bacterial infection, bacteremia, and colonization
were recorded. Comparisons were made with a cohort of 60 con-
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